Posts

Showing posts with the label post covid syndrome

StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy

Image
August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years. StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair. PCS consists of sequelae in one-third of COVID-19 patients and could potentially be permanent. The U.S. government estimated that between 7.7 to 23 million people are suffering from PCS in the United States. In Asia, PCS prevalence reaches 51%. Symptoms of PCS include breathlessness, persistent cough, fatigue, pain, brain fog, anxiety, depression, palpitations, dizziness, weakness, and sleep problem...